SCYNEXIS

About SCYNEXIS Board of Directors

Pamela J. Kirby, Ph.D. - Board of Directors, Chairman of the Board
Dr. Pamela Kirby is the Chairman of the Board for SCYNEXIS, Inc. She brings over 25 years experience in the pharmaceutical and biotechnology industries. Most recently, Dr. Kirby was the Chief Executive Officer of Quintiles Transnational Corporation, a provider of integrated product development and commercial solutions to the pharmaceutical and biotechnology industries. Dr. Kirby is currently a non-executive Director of Smith and Nephew plc, Novo Nordisk A/S, Informa plc and Curalogic A/S. Dr. Kirby began her career at Astra AB (now AstraZeneca), rising through several senior management positions before becoming Managing Director of the UK and Ireland subsidiaries in 1988 and being named Vice President, Corporate Strategy, Marketing and Business Development, in 1994. From there, she became Commercial Director at British Biotech plc (now Vernalis) and then Director of Global Strategic Marketing and Business Development in the pharmaceutical division of Hoffman-La Roche Ltd. She has a BSc in pharmacology and a Ph.D. in clinical pharmacology.

Ed Penhoet, Ph.D. - Board of Directors
Ed Penhoet is a director of Alta Partners which he joined in 2000. Dr. Penhoet is the president of the Gordon and Betty Moore Foundation's Science and Higher Education Programs. He is also the vice chairman of the Independent Citizens Oversight Committee, an organization created to oversee the California stem cell research initiative. Prior to joining Alta Partners, Ed was a co-founder of Chiron Corporation, where he served as president and chief executive officer from 1992 to 1998. For 10 years prior to founding Chiron, he was a faculty member of the Biochemistry Department of the University of California, Berkeley. He is the immediate past dean of the School of Public Health at the University of California, Berkeley. He is a member of the Institute of Medicine of the National Academy of Sciences, sits on the board of Kaiser Permanente, and has co-authored more than 50 scientific articles and papers. Dr. Penhoet earned his A.B. in Biology from Stanford University in 1963 and his Ph.D. in Biochemistry from the University of Washington in 1968. He was a post-doctoral fellow at the University of California, San Diego, from 1968 to 1970.

Patrick J. Langlois, Ph.D. - Board of Directors
Mr. Patrick Langlois is the General Partner of PJL Conseils, a consulting firm, since March 1st, 2005. He served as Vice Chairman of Aventis’ Management Board and Chief Financial Officer from May 2002 to September 2004 and Executive Vice President and Chief Financial Officer of Aventis S.A. from December 1999 to May 2002. At Aventis, Patrick Langlois was responsible for finance and corporate development functions as well as three global businesses: chemicals, protein therapeutics and animal health. Prior to joining Aventis, he was employed by the Rhône-Poulenc Group from 1975 to 1999, most recently as Chief Financial Officer and Member of the Executive Committee. Patrick Langlois received a License degree from the University of Rennes in 1967, a Ph.D. degree in Economics from the University of Rennes and was awarded a Diploma in Higher Banking Studies.

John H. Kim, MD, MBA - Board of Directors
John Kim, M.D., brings a medical and financial background to venture capital firm Burrill & Company. Prior to joining Burrill in 1998, Dr. Kim was a practicing surgeon. In addition, Dr. Kim also served as a member of the clinical faculty of the University of Illinois School of Medicine. Dr. Kim has had significant equity investment experience as well as having been part of the medical technology equity research team at Goldman, Sachs & Company immediately prior to joining Burrill. At Goldman Sachs, Dr. Kim was selected in a Reuter's survey of small to mid-cap companies as one of the top ten analysts serving the medical technology industry. Dr. Kim is a graduate of the Six-Year Honors Program in Medical Education at Northwestern University where he received both BS and MD degrees. He obtained his post-graduate medical education in Urology at Northwestern and completed a one-year fellowship in Tumor Cell Biology at the Northwestern University Cancer Center. Dr. Kim also received an MBA with distinction from the Wharton School of the University of Pennsylvania. Dr. Kim currently serves on the boards of directors of BioMimetic Pharmaceuticals, Corus Pharma, Morphotek, Odyssey Thera, Rejuvenon Corp., Sagres Discovery, SCYNEXIS, and Xerion Pharmaceuticals.

Jean-Yves Nothias, Ph.D. - Board of Directors
Jean-Yves Nothias is a managing director of SG Asset Management Alternative Investments (“SGAM”), where he leads the Biotechnology Team. Since joining SGAM in 2000, Nothias has built a team of professionals managing a global portfolio of 36 biotechnology companies. Previously, he was a biotechnology analyst for Hambrecht & Quist based in Paris and then for Oddo & Cie. Nothias is on the surveillance board of two French biotech companies, Cytomics Systems and Biosystems. Dr. Nothias holds a thesis in Molecular Biology from Université Paris VI and a master's degree in management from Université Paris Sorbonne. As a scientist, he worked at several research institutions in France and in the United States. He was a post-doctoral fellow at the Roche Institute of Molecular Biology in Nutley, N.J., from 1993 until 1995.

Laurent Arthaud - Board of Directors
Laurent Arthaud is currently a general partner with CDC Entreprises, a fund to fund capital firm based in Paris. Previously he was managing partner with Pharmavent Partners, also headquartered in Paris, and prior to Pharmavent Mr. Arthaud was in charge of the venture capital activities of the pharmaceutical leader Aventis and managed the venture capital fund Genavent. Mr. Arthaud started his career in 1986 at the INSEE (French Economic Statistics Institute), and then at the Forecasts Department of the French Ministry of Finances. In 1995, he joined the cabinet of French Prime Minister Alain Juppé as Technical Advisor in charge of workforce and unemployment matters. He joined Rhône-Poulenc in 1997 as Scientific Board General Secretary and was appointed to his present position following the creation of Aventis in 1999 from the merger of Rhone-Poulenc and Hoechst. Mr. Arthaud is a graduate from the "Ecole Polytechnique" of Paris and from the "Ecole Nationale de la Statistique et de l'Administration Economique".

Yves J. Ribeill, Ph.D. - President and Chief Executive Officer
Prior to organizing SCYNEXIS, Inc. in 2000, Dr. Yves Ribeill held various positions during a 20-year international pharmaceutical career with Aventis and its predecessor Rhone-Poulenc Rorer. His roles with those companies included Discovery Chemistry Group leader for Anti-Viral Research and later in the Central Nervous System Group in France. He later served as Director of Chemistry for the Anti-Infective Group. He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of the anti-bacterial Synercid in 1999. Dr. Ribeill is the author of more than 26 publications and 15 patents. He is a member of the Scientific Advisory Committee of the World Health Organization. Ribeill has a Ph.D. in Chemistry from the University of Montpellier in France.